Moderate riskFDA DrugClass II

Major Pharmaceuticals levothyroxine tablets recalled for subpotency

Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP, 25 mcg due to subpotency — meaning the tablets contain less active ingredient than labeled. This affects Lot N02212 with an expiration date of 07/2026. Patients taking subpotent levothyroxine may not receive the full intended dose of this thyroid hormone replacement medication.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have Levothyroxine Sodium Tablets, USP, 25 mcg (NDC 0904-6949-61) with Lot N02212.
  2. Contact your pharmacist or doctor if you have this lot — do not stop taking the medication without guidance.
  3. Your doctor may need to adjust your dose or switch you to a replacement supply.
  4. Report any adverse effects to your doctor or the FDA MedWatch program.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6949-61
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 12 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Classification
Class II
Recall number
D-0700-2026

In the FDA's words

Description
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6949-61 Subpotent Drug Lot#: N02212, Exp. Date 07/2026 Distribution: Nationwide in the USA. Affected quantity: N/A
Hazard
Subpotent Drug

12 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

PotencyDrugsSold nationwideMore from FDA Drug